Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 1;30(7):1127-1133.
doi: 10.1093/annonc/mdz128.

A Phase III, Randomized, Open-Label Study of ASP8273 Versus Erlotinib or Gefitinib in Patients With Advanced Stage IIIB/IV Non-Small-Cell Lung Cancer

Affiliations
Free PMC article

A Phase III, Randomized, Open-Label Study of ASP8273 Versus Erlotinib or Gefitinib in Patients With Advanced Stage IIIB/IV Non-Small-Cell Lung Cancer

R J Kelly et al. Ann Oncol. .
Free PMC article

Abstract

Background: ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI) specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating mutations or EGFR T790M resistance mutations. The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.

Patients and methods: This global, phase III, open-label, randomized study evaluated ASP8273 versus erlotinib/gefitinib in patients with locally advanced, metastatic, or unresectable stage IIIB/IV NSCLC with activating EGFR mutations. They were ineligible if they received prior chemotherapy for metastatic disease. The primary end point was progression-free survival (PFS), and secondary end points included overall survival, investigator-assessed PFS, best overall response rate (ORR), disease control rate, duration of response (DoR), and the safety/tolerability profile.

Results: Patients (n = 530) were randomized 1 : 1 to receive ASP8273 (n = 267) or erlotinib/gefitinib (n = 263). Patient demographics between both treatment groups were generally balanced. Median PFS was 9.3 months (95% CI 5.6-11.1 months) for patients receiving ASP8273 and 9.6 months (95% CI 8.8-NE) for the erlotinib/gefitinib group, with a hazard ratio of 1.611 (P = 0.992). The ORR in the ASP8273 group was 33% (95% CI 27.4-39.0) versus 47.9% (95% CI 41.7-54.1) in the erlotinib/gefitinib group. Median DoR was similar for both groups (9.2 months for ASP8273 versus 9.0 months for erlotinib/gefitinib). More grade ≥3 treatment-emergent adverse events (TEAEs) occurred in patients receiving ASP8273 than in those receiving erlotinib/gefitinib (54.7% versus 43.5%). An independent data monitoring committee carried out an interim safety analysis and recommended discontinuing the study due to toxicity and limited predicted efficacy of ASP8273 relative to erlotinib/gefitinib.

Conclusions: First-line ASP8273 did not show improved PFS or equivalent toxicities versus erlotinib/gefitinib.

Clinicaltrial.gov number: NCT02588261.

Keywords: ASP8273; EGFR inhibitor; non-small-cell lung cancer; phase III clinical trial.

Figures

Figure 1.
Figure 1.
Patient disposition.
Figure 2.
Figure 2.
Progression-free survival (FAS). CI, confidence interval; FAS, full analysis set.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Bell DW, Lynch TJ, Haserlat SM. et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. JCO 2005; 23(31): 8081–8092. - PubMed
    1. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008; 21(Suppl 2): S16–S22. - PubMed
    1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359(13): 1367–1380. - PubMed
    1. Esposito L, Conti D, Ailavajhala R. et al. Lung cancer: are we up to the challenge? Curr Genomics 2010; 11(7): 513–518. - PMC - PubMed
    1. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. JCO 2013; 31(8): 1070–1080. - PMC - PubMed

Publication types

Associated data

Feedback